Target intelligence / Profile preview

Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Target
KCNH2
Molecular classification
Ion channel, Voltage-gated potassium channel
01

Overview

Potassium voltage-gated channel subfamily H member 2 (KCNH2), commonly referred to as hERG, is a protein that forms the alpha subunit of the rapid delayed rectifier potassium channel (IKr) in the heart. This channel is fundamental for the repolarization phase of the cardiac action potential, effectively resetting the electrical state of the heart after each beat to allow for subsequent contraction [UniProt Q12809]. Proper functioning of KCNH2 is vital for maintaining a stable heart rhythm, and genetic mutations in the KCNH2 gene are the primary cause of Long QT syndrome type 2 (LQT2) [NCBI Gene 3757].

Beyond its physiological role, KCNH2 is highly susceptible to inhibition by a wide variety of structurally diverse drugs, including antihistamines, antipsychotics, and antibiotics [PubChem CID 3757]. This unintended drug-target interaction can lead to drug-induced Long QT syndrome and life-threatening ventricular arrhythmias such as Torsades de Pointes [StatPearls NBK554411]. Consequently, screening for hERG channel inhibition is a mandatory safety requirement in modern drug discovery to prevent cardiotoxicity [FDA/ICH E14/S7B].

Other names
hERGHuman ether-a-go-go-related geneERG1Kv11.1HERG1Potassium channel subfamily H member 2
02

Mechanism of action

Blockade of the rapid delayed rectifier potassium current (IKr)

03

Biological functions

Cardiac repolarizationRegulation of heart rhythmSignal transduction
04

Disease associations

Cardiovascular diseaseLong QT syndrome type 2Short QT syndrome type 1Cardiac arrhythmiaSudden infant death syndrome
05

Safety considerations

Drug-induced Long QT syndrome (diLQTS)Torsades de Pointes (TdP)Sudden cardiac deathPro-arrhythmic risk
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

QTc interval prolongationKCNH2 gene mutationsT-wave morphology changes

Beyond the preview

Go deeper on Potassium voltage-gated channel subfamily H member 2 (KCNH2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potassium voltage-gated channel subfamily H member 2 (KCNH2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call